Clinical Trial Update: Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intranasal midazolam (USL261) for seizure clusters in epilepsy was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• USL261

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Epilepsy | Phase 3 | Status: TERMINATED | Results posted: 2019-05-31